This is Not a History Lesson; This is Agitation: A Call for a Methodology of Diffraction in US-Based Community Psychology

被引:19
|
作者
Langhout, Regina Day [1 ]
机构
[1] Univ Calif Santa Cruz, Santa Cruz, CA 95064 USA
关键词
Community psychology; Training; Reflexivity; Diffraction; Competencies; EMPOWERMENT;
D O I
10.1002/ajcp.12039
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Agitation, as deployed by the Industrial Areas Foundation (IAF), occurs when imaginations and curiosities are piqued, and self-interest is made visible. In this framework, agitation is a step in creating change. In this paper, I outline two agitations within US-based community psychology. I then describe a third agitation that is underway; I add my voice and call for a methodology of diffraction as a contribution to critical reflexivity practices within US-based community psychology. Consistent with the IAF framework, I do not provide solutions. I write this paper as a provocation to help us think imaginatively and creatively about our actions and future, so that we can consider the paradigm shifts needed to move into critical ways of understanding connection, responsibility, accountability, and creating changeof interest during Swampscott and today.
引用
收藏
页码:322 / 328
页数:7
相关论文
共 18 条
  • [11] Local Ancestry Inference in a Large US-Based Hispanic/Latino Study: Hispanic Community Health Study/Study of Latinos (HCHS/SOL)
    Browning, Sharon R.
    Grinde, Kelsey
    Plantinga, Anna
    Gogarten, Stephanie M.
    Stilp, Adrienne M.
    Kaplan, Robert C.
    Aviles-Santa, M. Larissa
    Browning, Brian L.
    Laurie, Cathy C.
    G3-GENES GENOMES GENETICS, 2016, 6 (06): : 1525 - 1534
  • [12] CRAFTING AND SUSTAINING A GLOBAL COMMUNITY OF CARING: OUTCOMES FROM 10 YEARS OF A US-BASED UNIVERSITY STUDENT AND FACULTY PAR PROJECTS IN MALAWI
    Barber, E.
    Miller, D.
    Potts, A.
    Bradsher, T.
    Davis, M.
    Martin, R.
    Reynolds, K.
    Snyder, J.
    Nock, D.
    Bottomley, K.
    Kapenuka, L.
    Kawiza, G.
    Ziaya, C.
    Ngalande, T.
    Phetekwere, J.
    Kamwendo, H.
    Misomale, A.
    6TH INTERNATIONAL CONFERENCE OF EDUCATION, RESEARCH AND INNOVATION (ICERI 2013), 2013, : 494 - 500
  • [13] Real World Experience with Pegylated Interferon/Ribavirin Therapy for Hepatitis C in a US-based Community Practice: How Well Are We Doing?
    Lalos, Alexander
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2011, 106 : S108 - S109
  • [14] How Do We Explain the Social, Political, and Economic Determinants of Health? A Call for the Inclusion of Social Theories of Health Inequality Within US-Based Public Health Pedagogy
    Harvey, Michael
    PEDAGOGY IN HEALTH PROMOTION, 2020, 6 (04) : 246 - 252
  • [15] Piling it on: Perceived stress and lack of access to resources among US-based LGBTQ plus community members during the COVID-19 pandemic
    Levandowski, Brooke A.
    Miller, Susan B.
    Ran, Davy
    Pressman, Eva A.
    Van der Dye, Timothy
    PLOS ONE, 2022, 17 (07):
  • [16] Medical resource utilization among community-acquired pneumonia patients initially treated with levofloxacin 750 mg daily versus ceftriaxone 1000 mg plus azithromycin 500 mg daily: A US-based study
    Frei, C. R.
    Jaso, T. C.
    Mortensen, E. M.
    Restrepo, M. I.
    Raut, M. K.
    Oramasionwu, C. U.
    Ruiz, A. D.
    Makos, B. R.
    Ruiz, J. L.
    Attridge, R. T.
    Mody, S. H.
    Fisher, A.
    Schein, J. R.
    CURRENT MEDICAL RESEARCH AND OPINION, 2009, 25 (04) : 859 - 868
  • [17] Objective response rate (ORR) and time to treatment failure (TTF) for BRAF v600 mutated metastatic melanoma (BRAF plus MM) patients receiving first-line (1L) targeted therapy (TT) or immunooncology (I-O) agents at US-based community oncology practices
    Luke, Jason J.
    Ghate, Sameer R.
    Kish, Jonathan
    Lee, Choo Hyung
    McAllister, Lindsay
    Mehta, Sonam
    Ndife, Briana
    Feinberg, Bruce A.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [18] Objective response rate (ORR) and time to treatment failure (TTF) for BRAF v600 mutated metastatic melanoma (BRAF plus MM) patients receiving first-line (1L) treatment with dabrafenib/trametinib (D plus T) v ipilimumab/nivolumab (I plus N) and nivolumab or pembrolizumab (N/P) monotherapy at US-based community oncology practices.
    Feinberg, Bruce A.
    Kish, Jonathan
    Ghate, Sameer R.
    Ndife, Briana
    Lee, Choo Hyung
    McAllister, Lindsay
    Mehta, Sonam
    Nakasato, Antonio Reis
    Luke, Jason J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)